| BACKG ROU N D
Since 2013, the Leading International Fungal Education (LIFE) portal has facilitated an estimation of the global burden of serious fungal diseases. By the end of 2017, burden of fungal disease estimates was published for 57 countries and presented in public for another 18 (https://www.gaffi.org). The 2017 global estimates indicated that more than 10 000 000 cases of fungal asthma, ~3 000 000 cases of chronic pulmonary aspergillosis, ~1 000 000 cases of fungal keratitis, ~700 000 cases of invasive candidiasis, ~500 000 cases of Pneumocystis jirovecii pneumonia, ~250 000 cases of invasive aspergillosis, ~223 100 cases of cryptococcal meningitis complicating HIV/AIDS, and ~100 000 cases of disseminated histoplasmosis occur annually.
1 A more conservative overview of the burden of fungal infections worldwide has been derived from FungiScope®, a worldwide operating registry ( Figure 1 ).
Overall, the majority of fungal infections, in particular the majority of AIDS-related mycoses, 2 endemic mycoses, subcutaneous mycoses, and fungal keratitis, are found in low-and middle-income countries (LMIC), where the expertise and resources to manage these problems are limited. 3 Further, in contrast to some national guidelines focusing on specific regions only, 4 the vast majority of international guidelines on fungal infections for the management of fungal infections do not focus on providing specific recommendations for LMIC. 5 In recent years, new groups of patients at risk of developing invasive fungal diseases (IFD) have been identified. 6 Invasive aspergillosis is frequently seen in critically ill patients with influenza. 7, 8 Biological therapies, such as tumour necrosis factor-α inhibitors, and new small molecule kinase inhibitors, such as ibrutinib and idelalisib increase the risk of IFD. [9] [10] [11] To further complicate the management of fungal infections, emergence of antifungal resistance in Candida and Aspergillus spp., driven by widespread agricultural use of antifungal compounds, has become increasingly apparent. 12 First described in Japan in 2009, Candida auris has become a global multidrug-resistant pathogen with the ability to persist in the inanimate environment, thus perpetuating the risk of further spread of the organisms. [13] [14] [15] New medically important fungal pathogens continue to be reported, as exemplified by Lomentospora prolificans, or Emergomyces spp. that cause disseminating IFD in severely immunosuppressed persons. [16] [17] [18] [19] [20] Moreover, new antifungal agents have recently become available or are being developed that warrant up-to-date guidance on optimal treatment of IFDs. [21] [22] [23] Finally, the increasing availability of new nucleic acid amplification assays, blood culture detection systems, lateral flow devices, as well as matrix-assisted laser desorption time of flight (MALDI-TOF) mass spectrometry for detection of medically important fungi and laboratory diagnosis of invasive mycoses warrants guidance in their use in clinical practice. [24] [25] [26] [27] To respond adequately to these tasks, international societies of medical mycology have joined forces with a goal of improving diagno- 
| ECMM: HIS TORY, MISS I ON , AND WORKING G ROUPS
The ECMM serves as a confederating organisation for National 
| ECMM E XCELLEN CE CENTRE (EC) INITIATIVE
An ECMM EC is an institution designated by the ECMM Board to form part of an international collaborative network. In line with the ECMM policy and strategy, an ECMM EC participates in the strengthening of country resources, in terms of information, services, research, and training, in support of national health development.
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An ECMM EC designation provides institutions with enhanced visibility and recognition by national authorities, calling public attention to the health issues on which they work. It opens up improved opportunities to exchange information and develop technical cooperation with other institutions, in particular at international level, and to mobilise additional resources from funding partners.
Any centre, which fulfils the ECMM-related requirements, is encouraged to apply for a designation. Centres will only be designated as ECMM EC after careful onsite auditing. At least one centre per country is The audit takes place by collecting data on how laboratory diagnosis is performed and on how clinical management of IFD is effectively executed. As a basis of the laboratory audit, the best practice recommendations for the diagnosis of serious fungal diseases will be used.
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Presently, five ECMM EC with diamond status and one with silver status (Zagreb, Croatia) are already implemented, and one EC (Houston, USA) is under evaluation (Figure 3 ).
| ECMM EC Study Coordinator
The ECMM has appointed an ECMM study coordinator who will coordinate within the ECs. The study coordinator Alexandre Alanio, France, is in charge of following the corresponding studies. His role is to help ECs to implement the studies locally (writing protocols, discussing the implementation of studies locally) and to act as a facilitator. Regular appointments at the different annual meetings (TIMM, ISHAM, ECCMID) will be organised to help the study coordinator follow the progress of the project (implementation, number of cases enrolled).
The study coordinator will discuss on a regular basis (teleconference, Skype ® ) with one representative of each centre designated by the ECs for the corresponding study. Next to that, the study coordinator will help to collect the data, analyse the results, and write the manuscript.
| ECMM G LOBAL G U IDELINE S INITIATIVE/ORPHAN DIS E A S E G UIDAN CE
In the context of a growing population of immunocompromised patients at risk of opportunistic infections, the prevalence of IFD, including infections due to Candida, Aspergillus, and emerging and often drug-resistant moulds, such as Mucorales, is on the rise. 
| Systematic approach
The guideline follows the structure and definitions of the ESCMID Guideline on candidiasis and the ESCMID/ECMM guidelines on rare IFD, which are in accordance with the GRADE and AGREE systems. 34, 35 The fact that most IFD are orphan diseases necessitated some adaptation, however. Formal meta-analyses will not be conducted for the guidelines on mucormycosis, rare mould diseases, rare yeast diseases, and endemic mycoses, because prospective comparative clinical trials are very rare exceptions in these >40 different disease entities.
The general principle behind the PICO (population, intervention, comparison, outcome) approach is rigourously applied, but in this set of ECMM guidelines, PICO comes in the form of streamlined tables ( Table 2) . Treatment strategies and diagnostic assays are both regarded as interventions, because they have the potential to alter a patient's course. The fixed sequence of the seven columns is predefined and follows the logic of the ECMM guideline approach of maximising transparency. First, a population is defined. Then, the intention or objective is stated, followed by the intervention. For that logical sequence, the strength of recommendation and the quality of evidence are provided, followed by the references on which the recommendation is based. A comment may be added as appropriate.
| Definition of contributorship and authorship
Members of the group are experts involved in diagnosing or treat- 
| Grades of Recommendations, Assessment, Development, and Evaluation' (GRADE)
Every recommendation within the ECMM guidelines aims to indicate clearly the intention (eg, improved survival) and to describe the diagnostic or therapeutic option (intervention). Therefore, the guidelines
Centers-Distribution by Country (July  2018) follow the principles of GRADE (Table 3) . For every recommendation, the following three questions are considered:
What do clinicians want (outcomes)? What is their intention?
2. Which option is better for patients? What intervention is needed to reach the desired outcome?
3.
Review the chosen option whether it is truly better or not by adequate review of the literature.
| Appraisal of Guidelines, Research and Evaluation (AGREE)
A system for guideline development and indeed for systematically assessing the quality of guidelines is useful to enable comparison of different guidelines and to facilitate clinically and policy-driven decisions.
The Appraisal of Guidelines, Research and Evaluation (AGREE) is an internationally validated, rigourously developed tool used to evaluate independent domains of guideline development including: scope and purpose, stakeholder involvement, rigour of development, clarity and presentation, applicability, and editorial independence. 36 Overall, consensus is that the AGREE items are useful in supporting the practical application of guidelines. 37 Table 4 Together with other leading organisations in the field, the ECMM will continue to spearhead innovative initiatives that serve the long-term goal to reduce IFD-related morbidity and mortality. A.C.P. has received research grants and/or given paid talks to Pfizer, 
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TA B L E 3 GRADE, SoR and QoE in ECMM guidelines

Strength of recommendation (SoR) Definition
